Clinical Trial

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

Study acronym: FEND-AMI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
Protocol Amendment History 5 changes
critical Recruitment opened 2026-08-11
minor Trial arms changed: 3 -> 2 2026-08-11
notable Primary completion pushed: 2026-03 -> 2026-12-30 2026-08-11
minor Completion pushed: 2026-09 -> 2027-12-30 2026-08-11
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT06548204
Lead Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions ST-segment Elevation Myocardial Infarction (STEMI)
Enrollment 152 participants
Start Date 2025-01-20
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10